VYCO · Vycor Medical Inc
Substantial doubt about the company's ability to continue as a going concern.
“The Company has incurred losses since its inception, including a net loss of $2,180 for the six months ended June 30, 2026 and has not generated sufficient positive cash flows from operations. As of June 30, 2026 the Company had a working capital deficiency of $4,294,543 which includes related party liabilities of $3,800,538. These conditions, among others, raise substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.4M | $1.46M | $1.36M | $1.2M | $1.33M | $1.61M | $1.68M | $1.8M | $2.18M | — | — | — | — | — | — | — | |
| USD/shares | $0.00 | -$0.01 | -$0.01 | -$0.01 | -$0.02 | -$0.03 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | $0.00 | -$0.01 | -$0.01 | -$0.01 | -$0.02 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 33.37M | 32.88M | 32.6M | 31.71M | 29.63M | 26.1M | 23.96M | 21.6M | 18.37M | 11.07M | 10.84M | 10.27M | 6.32M | 5.64M | 5.2M |
| shares | — | 33.37M | 32.88M | 32.6M | 31.71M | 29.63M | 26.1M | 23.96M | 21.6M | 18.37M | 11.07M | 10.84M | 10.27M | 6.32M | 5.64M | 5.2M |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 37 similar-size Medical Devices companies (of 145 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Vycor Medical Inc | $1,796,070 | $1,515,744 | — | — | — | — |
| Nova Vision Inc | $67,330 | $73,580 | — | — | — | — |
| NovaVision | — | — | $82,006 | $92,074 | $119,385 | $102,483 |
| Vycor Medical | — | — | $1,378,598 | $1,130,915 | $1,273,602 | $1,039,562 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| United States | $1,858,494 | $1,585,644 | $1,453,895 | $1,214,723 | $1,374,770 | $1,125,226 |
| Europe | $4,906 | $3,680 | $6,709 | $8,266 | $18,217 | $16,819 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Vycor Medical Inc | $493,787 | $353,052 | — | — |
| Nova Vision Inc | -$183,878 | -$177,917 | — | — |
| Corporate | -$276,009 | -$184,280 | -$151,846 | -$322,490 |
| NovaVision | — | — | -$191,810 | -$223,351 |
| Vycor Medical | — | — | $383,847 | $239,327 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Vycor Medical Inc | 27.5% | 23.3% | — | — |
| Nova Vision Inc | -273.1% | -241.8% | — | — |
| NovaVision | — | — | -233.9% | -242.6% |
| Vycor Medical | — | — | 27.8% | 21.2% |